Michael Jones, MD
Medical Oncology · Fond du Lac, WINPI 1164403226
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,075 of the $8,978 with a category attached, or 89.9%. Myriad Genetic Laboratories, Inc. accounts for 99.6% of it on its own, with 2 other manufacturers making up the rest. 2024 is the largest year on record at $8,941, more than ten times the $14 reported in 2021.
Across 8 payments — averaging $1122.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Genetic Laboratories, Inc.$9K
- Gilead$23
- Acrotech Biopharma Inc.$14
What the payments were for
- Consulting fees$8,07590%
- Travel & lodging$86610%
- Food & beverage$230%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | 6 | $8,941 |
| Gilead | 1 | $23 |
| Acrotech Biopharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PreciseTumor$8,794
How this compares
$8,978 in reported general payments places this provider in the 80th percentile of 54 medical oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 43 | $594,974 |
| RevlimidLenalidomide | 25 | $394,458 |
| IbrancePalbociclib | 20 | $285,804 |
| ImbruvicaIbrutinib | 12 | $211,130 |
| LynparzaOlaparib | 15 | $132,852 |
| GleevecImatinib Mesylate | 17 | $121,604 |
| EliquisApixaban | 31 | $17,251 |
| Abiraterone Acetate | 23 | $9,411 |
| Exemestane | 37 | $4,200 |
| Anastrozole | 167 | $3,379 |
| Hydroxyurea | 72 | $1,776 |
| Tamoxifen Citrate | 46 | $1,714 |
| Prochlorperazine Maleate | 80 | $889 |
| Dexamethasone | 67 | $789 |
| Letrozole | 28 | $576 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Fond du Lac
- Alexandria PhanMilwaukee$260K
- Joshua LangMadison$114K
- Dustin DemingMadison$100K
- Kari WisinskiMadison$43K
- Hui-Zi ChenMilwaukee$41K
- Justine BruceMadison$25K
- Francis CuevasFranklin$14K
- Glenn LiuMadison$13K
- Toby CampbellMadison$12K
- Anand PatelBrookfield$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.